Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With or Without Lenalidomide in Relapsed/Refractory T-cell Lymphoma
NCT03011814Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Mar 2017
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by City of Hope. Primary endpoints: CTCL specific response assessed by Lugano Classification at 12 months, Dose limiting toxicity at 84 days and 8 more. Started Mar 2017; status: recruiting.
02
Drugs
durvalumab
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03011814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011814.